What is the appropriate management for an elderly long‑term care patient on Eliquis (apixaban) 2.5 mg who has hyperlipidemia, anemia, a localized right‑leg mass with +3 edema, left‑shoulder edema, and chronic hemiplegia/hemiparesis from a prior left‑sided cerebral infarction?

Urgent Evaluation for Deep Vein Thrombosis Required

This patient with unilateral +3 right leg edema and a localized mass on anticoagulation requires immediate vascular ultrasound to rule out acute DVT, as the current apixaban 2.5 mg dose may be inadequate for acute VTE treatment if present.

Immediate Assessment

The clinical presentation demands urgent action:

• Unilateral +3 edema with a localized mass is concerning for acute DVT, particularly in a patient with prior stroke and immobility from hemiplegia
• The left shoulder edema is likely unrelated (possibly related to hemiplegia/positioning) but the asymmetric leg findings are high-risk
• Order compression ultrasound of the right lower extremity immediately 1

Critical Dosing Issue

The patient is currently on apixaban 2.5 mg twice daily. This dose is only appropriate for:

• Secondary VTE prevention (after ≥6 months of treatment) 1
• Atrial fibrillation in patients meeting dose-reduction criteria 1
• Post-surgical DVT prophylaxis 1

If acute DVT is confirmed, this dose is grossly inadequate. Acute DVT treatment requires:

• Apixaban 10 mg twice daily for 7 days, then 5 mg twice daily 1

Management Algorithm

If DVT is Confirmed:

1. Immediately increase apixaban to 10 mg twice daily for 7 days, then 5 mg twice daily 1
2. Continue treatment dose for minimum 6 months 2, 3
3. After 6 months, reassess for extended-phase therapy:
   • Recommend extended anticoagulation since this would be unprovoked VTE (or provoked by persistent immobility) 3
   • After completing 6 months at treatment dose, reduce to apixaban 2.5 mg twice daily for long-term secondary prevention 2, 3, 1

If No DVT is Found:

1. Verify the indication for current apixaban 2.5 mg dose:

   • If for atrial fibrillation: Confirm patient meets dose-reduction criteria (≥2 of: age ≥80, weight ≤60 kg, creatinine ≥1.5 mg/dL) 1
   • If dose-reduction criteria are NOT met, increase to 5 mg twice daily 1
   • If for prior VTE secondary prevention: Continue current dose 2, 3

2. Evaluate alternative causes of edema:

   • Check renal function, albumin, BNP for cardiac/renal/hepatic causes
   • Consider venous insufficiency from immobility/hemiplegia
   • Assess for cellulitis or other infection

Key Pitfalls to Avoid

Most common error: Underdosing apixaban in elderly patients. Studies show 75% of inappropriate dosing involves giving lower doses than indicated 4. The 2.5 mg dose is frequently misused when 5 mg is appropriate.

Bleeding risk with anemia: This patient has documented anemia. While anemia increases bleeding risk (adjusted HR 1.92), it does NOT increase stroke risk and should not prevent appropriate anticoagulation 5. Apixaban maintains favorable safety compared to warfarin even in anemic patients 5.

Immobility as persistent risk factor: The hemiplegia/hemiparesis creates ongoing VTE risk. If DVT is confirmed, this patient will likely need indefinite anticoagulation at reduced dose (2.5 mg twice daily) after completing initial treatment 3.

Monitoring Considerations

Given this patient's complexity (elderly, long-term care, anemia, immobility):

• Monitor hemoglobin closely during any dose escalation
• Recent evidence suggests therapeutic drug monitoring may benefit high-risk elderly patients on apixaban, though not routinely required 6
• Reassess anticoagulation indication and bleeding risk at least annually 3

The current clinical picture suggests either acute DVT requiring immediate dose escalation, or chronic venous insufficiency/lymphedema from immobility. Ultrasound imaging is the critical next step that determines all subsequent management.